Value-Based Care in Lung Cancer
- PMID: 27256872
- PMCID: PMC4978558
- DOI: 10.1634/theoncologist.2016-0116
Value-Based Care in Lung Cancer
Abstract
Since the beginning of the 21st century, the treatment of lung cancer has changed dramatically. New treatments are improving survival outcomes for patients but have led to dramatic increases in cost. In a value-based payment system, patients should have access to comprehensive outcome measurements, including survival rates, quality of life, and cost. High value in cancer care will optimize the outcomes that matter to patients relative to cost.
Conflict of interest statement
Disclosures of potential conflicts of interest may be found at the end of this article.
References
-
- National Cancer Institute. National Expenditures for Cancer Care. Available at http://costprojections.cancer.gov/expenditures.html. Accessed March 15, 2016.
-
- Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—The pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140:1225–1236. - PubMed
-
- Yong PL, Olsen LA, McGinnis JM.(Institute of Medicine [U.S.] Roundtable on Value & Science-Driven Health Care). Value in Health Care: Accounting for Cost, Quality, Safety, Outcomes, and Innovation Washington, DC: National Academies Press,201029–38. Available from: http://www.ncbi.nlm.nih.gov/books/NBK50926/. - PubMed
-
- VanLare JM, Conway PH. Value-based purchasing—National programs to move from volume to value. N Engl J Med. 2012;367:292–295. - PubMed
-
- Gruessner V. CMS innovation center’s role in improving value-based care. Available at http://healthpayerintelligence.com/news/cms-innovation-centers-role-in-i.... Accessed March 15, 2016.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical